Capricor Therapeutics (CAPR) Scheduled to Post Earnings on Wednesday

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analysts' expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, analysts expect Capricor Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Capricor Therapeutics Stock Performance

Shares of CAPR traded down $0.22 during mid-day trading on Wednesday, reaching $18.23. 1,345,597 shares of the company's stock were exchanged, compared to its average volume of 2,347,247. The business's fifty day simple moving average is $12.95 and its 200-day simple moving average is $7.75. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $23.40.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Maxim Group raised their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Oppenheimer reiterated an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They issued an "overweight" rating and a $35.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday, September 20th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $24.67.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business's stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 12.00% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.